Quest Diagnostics Stock Gains 5% After Q1 Earnings Exceed Analyst Expectations

Key Stats for Quest Diagnostics Stock

• Price change for Quest Diagnostics stock: 4%
• $DGX Share Price as of Apr. 21: $205
• 52-Week High: $214
• $DGX Stock Price Target: $218

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

What Happened?

Quest Diagnostics (DGX) stock moved higher after the company reported Q1 2026 results that beat on both revenue and earnings.

• Revenue came in at $2.90 billion, ahead of the $2.83 billion estimate.
• Adjusted EPS of $2.50 topped the $2.37 forecast by a meaningful margin.
• Management also raised full-year guidance, now targeting revenue of $11.78 to $11.9 billion and adjusted EPS of $10.63 to $10.83.

The beat was driven by broad-based demand across physician, hospital, and consumer channels.

• Organic revenue grew 9% year-over-year.
• Total volume was up nearly 11%, boosted significantly by two new large partnerships with Fresenius Medical Care and Corewell Health, which together accounted for about 7% of the volume growth on their own.

See analysts’ growth forecasts and price targets for Quest Diagnostics stock (It’s free) >>>

What the Market Is Telling Us About Quest Diagnostics Stock

Quest Diagnostics stock has been quietly building momentum, and this quarter reinforces why.

The company is growing in the right places.

• Its Alzheimer’s blood-test business more than doubled year over year.
• Advanced cardiometabolic testing is experiencing double-digit growth, supported by new American Heart Association guidelines that recommend tests such as Lp(a) and ApoB for the first time.
• Consumer health revenue is growing even faster, with Quest’s direct channel posting high-20s growth and its wellness partnerships growing even quicker.

CEO Jim Davis framed the broader vision well: the company sees a future where lab results, wearable data, and AI combine before a doctor’s visit rather than after.

Quest is already building toward that with its AI Companion tool on the MyQuest app, which patients used roughly 350,000 times in Q1 alone to interpret their own lab results.

On the cost side, AI and automation are also helping. Customer service productivity jumped 40% in Q1 among agents using AI tools. The Invigorate program continues to deliver 3% in annual cost savings.

There are near-term headwinds worth noting.

• Fuel costs are expected to add $7 to $10 million in incremental expense.
• Project Nova, a multi-year operational overhaul, will create about $0.25 of EPS dilution this year, weighted toward the second half.
• But neither issue changes the underlying growth story.

For investors watching Quest Diagnostics stock, this quarter confirmed the company is executing well across multiple growth drivers simultaneously.

Estimate a company’s fair value instantly (Free with TIKR) >>>

How Much Upside Does Quest Diagnostics Stock Have From Here?

With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.

All it takes is three simple inputs:

1. Revenue Growth
2. Operating Margins
3. Exit P/E Multiple

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

See a stock’s true value in under 60 seconds (Free with TIKR) >>>

Looking for New Opportunities?

• See what stocks billionaire investors are buying so you can follow the smart money.
• Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
• The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!